JP5596047B2 - ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤 - Google Patents

ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤 Download PDF

Info

Publication number
JP5596047B2
JP5596047B2 JP2011536613A JP2011536613A JP5596047B2 JP 5596047 B2 JP5596047 B2 JP 5596047B2 JP 2011536613 A JP2011536613 A JP 2011536613A JP 2011536613 A JP2011536613 A JP 2011536613A JP 5596047 B2 JP5596047 B2 JP 5596047B2
Authority
JP
Japan
Prior art keywords
compound
cancer
pharmaceutically acceptable
composition
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011536613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509279A (ja
JP2012509279A5 (enExample
Inventor
デイビッド ラウファー，
パン リー，
ディーン シャノン，
チアンリン リャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2012509279A publication Critical patent/JP2012509279A/ja
Publication of JP2012509279A5 publication Critical patent/JP2012509279A5/ja
Application granted granted Critical
Publication of JP5596047B2 publication Critical patent/JP5596047B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011536613A 2008-11-19 2009-11-18 ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤 Expired - Fee Related JP5596047B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11603308P 2008-11-19 2008-11-19
US61/116,033 2008-11-19
PCT/US2009/064909 WO2010059668A1 (en) 2008-11-19 2009-11-18 A triazolothiadiazole inhibitor of c-met protein kinase

Publications (3)

Publication Number Publication Date
JP2012509279A JP2012509279A (ja) 2012-04-19
JP2012509279A5 JP2012509279A5 (enExample) 2012-12-27
JP5596047B2 true JP5596047B2 (ja) 2014-09-24

Family

ID=42027848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536613A Expired - Fee Related JP5596047B2 (ja) 2008-11-19 2009-11-18 ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤

Country Status (18)

Country Link
US (3) US8217056B2 (enExample)
EP (1) EP2365977B1 (enExample)
JP (1) JP5596047B2 (enExample)
KR (1) KR20110094285A (enExample)
CN (1) CN102216309B (enExample)
AR (1) AR074379A1 (enExample)
AU (1) AU2009316756B2 (enExample)
BR (1) BRPI0921509A2 (enExample)
CA (1) CA2743000A1 (enExample)
CL (1) CL2011001152A1 (enExample)
ES (1) ES2393693T3 (enExample)
IL (1) IL212906A0 (enExample)
MX (1) MX2011005250A (enExample)
NZ (1) NZ592825A (enExample)
RU (1) RU2011124894A (enExample)
TW (1) TW201024309A (enExample)
WO (1) WO2010059668A1 (enExample)
ZA (1) ZA201103170B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166008A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
JP5596047B2 (ja) * 2008-11-19 2014-09-24 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤
SI2435443T1 (sl) * 2009-05-28 2013-12-31 Vertex Pharmaceuticals Incorporated Aminopirazol triazolotiadiazolni inhibitorji c-met protein kinaze
CA2762186A1 (en) * 2009-05-28 2010-12-02 Vertex Pharmaceuticals Incorporated Substituted pyrazole inhibitors of c-met protein kinase
WO2010138673A1 (en) * 2009-05-28 2010-12-02 Vertex Pharmaceuticals Incorporated Inhibitors of c-met protein kinase
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法
CN109897054B (zh) * 2017-12-08 2021-12-10 中国药科大学 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080080584A (ko) * 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
JP2009538899A (ja) * 2006-05-30 2009-11-12 ファイザー・プロダクツ・インク トリアゾロピリダジン誘導体
CN101678014B (zh) * 2007-05-21 2012-12-12 Sgx药品公司 杂环激酶调节剂
JP5596047B2 (ja) * 2008-11-19 2014-09-24 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤

Also Published As

Publication number Publication date
US20110207774A1 (en) 2011-08-25
AR074379A1 (es) 2011-01-12
KR20110094285A (ko) 2011-08-23
AU2009316756A1 (en) 2010-05-27
TW201024309A (en) 2010-07-01
US8343998B2 (en) 2013-01-01
EP2365977B1 (en) 2012-10-03
CA2743000A1 (en) 2010-05-27
WO2010059668A1 (en) 2010-05-27
BRPI0921509A2 (pt) 2016-03-08
ZA201103170B (en) 2012-08-29
US20100234423A1 (en) 2010-09-16
AU2009316756B2 (en) 2016-02-25
NZ592825A (en) 2013-01-25
IL212906A0 (en) 2011-07-31
JP2012509279A (ja) 2012-04-19
EP2365977A1 (en) 2011-09-21
CL2011001152A1 (es) 2012-02-24
US8217056B2 (en) 2012-07-10
CN102216309A (zh) 2011-10-12
ES2393693T3 (es) 2012-12-27
MX2011005250A (es) 2011-07-29
US20110301195A1 (en) 2011-12-08
RU2011124894A (ru) 2012-12-27
CN102216309B (zh) 2014-05-07

Similar Documents

Publication Publication Date Title
JP5596047B2 (ja) ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤
US8263776B2 (en) Inhibitors of c-Met protein kinase
US8269013B2 (en) Substituted pyrazole inhibitors of c-Met protein kinase
EP2435443B1 (en) Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase
HK1158646A (en) A triazolothiadiazole inhibitor of c-met protein kinase
HK1158646B (en) A triazolothiadiazole inhibitor of c-met protein kinase
HK1169401A (en) Substituted pyrazole inhibitors of c-met protein kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140520

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140620

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140805

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140806

R150 Certificate of patent or registration of utility model

Ref document number: 5596047

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees